Free Trial

Johnson & Johnson (JNJ) Stock Forecast & Price Target

Johnson & Johnson logo
$193.86 +0.64 (+0.33%)
As of 01:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
8
Buy
16

Based on 24 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 8 have given a hold rating, 14 have given a buy rating, and 2 have given a strong buy rating for JNJ.

Consensus Price Target

$200.06
3.20% Upside
According to the 24 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $200.06. The highest price target for JNJ is $215.00, while the lowest price target for JNJ is $153.00. The average price target represents a forecasted upside of 3.20% from the current price of $193.86.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JNJ Analyst Ratings Over Time

TypeCurrent Forecast
10/20/24 to 10/20/25
1 Month Ago
9/20/24 to 9/20/25
3 Months Ago
7/22/24 to 7/22/25
1 Year Ago
10/21/23 to 10/20/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
Hold
8 Hold rating(s)
10 Hold rating(s)
11 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$200.06$178.80$172.87$175.93
Forecasted Upside3.20% Upside1.61% Upside2.96% Upside6.55% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Johnson & Johnson Stock vs. The Competition

TypeJohnson & JohnsonMedical CompaniesS&P 500
Consensus Rating Score
2.74
2.33
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside3.42% Upside1,357.67% Upside13.61% Upside
News Sentiment Rating
Positive News

See Recent JNJ News
Neutral News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/20/2025Daiwa Capital Markets
2 of 5 stars
 UpgradeNeutralOutperform$203.00+5.04%
10/16/2025HSBC
2 of 5 stars
 Boost TargetBuy$210.00 ➝ $215.00+11.25%
10/15/2025Argus
4 of 5 stars
David Toung
3 of 5 stars
Set Target$210.00+10.16%
10/15/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$174.00 ➝ $209.00+9.49%
10/15/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Target$190.00-0.46%
10/15/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetHold$165.00 ➝ $190.00-0.46%
10/15/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$213.00 ➝ $215.00+12.30%
10/15/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$198.00 ➝ $204.00+6.87%
10/14/2025Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
10/14/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$190.00 ➝ $214.00+13.73%
10/10/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$209.00+9.63%
10/9/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$186.00 ➝ $212.00+11.19%
10/8/2025Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHold (C+)Buy (B-)
10/6/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetMarket Perform$172.00 ➝ $193.00+2.38%
10/3/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetEqual WeightOverweight$170.00 ➝ $212.00+13.99%
9/23/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$167.00 ➝ $206.00+18.24%
9/16/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$185.00 ➝ $200.00+13.33%
7/23/2025Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy
7/17/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight
7/17/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$165.00 ➝ $176.00+8.13%
5/13/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
5/13/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform$169.00 ➝ $153.00-0.57%
4/24/2025Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$190.00+25.12%
10/16/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight$215.00 ➝ $215.00+30.70%
7/23/2024Daiwa America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
7/18/2024TD Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower Target$195.00 ➝ $185.00+18.03%
7/18/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$195.00 ➝ $185.00+18.38%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:32 PM ET.


Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 14, 2025. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Johnson & Johnson:

  • The current stock price is around $190, reflecting a strong market position and investor confidence in the company's future performance.
  • Johnson & Johnson has recently updated its earnings guidance for FY 2025, projecting earnings per share between 10.800 and 10.900, which is above the consensus estimate, indicating potential for growth.
  • The company reported a robust revenue of $24.02 billion for the last quarter, showcasing its strong sales performance and operational efficiency.
  • With a return on equity of 32.49%, Johnson & Johnson demonstrates effective management of shareholder equity, which is a positive indicator for investors looking for profitable companies.
  • The company has a consistent dividend payout, with a recent quarterly dividend of $1.30, translating to an annualized dividend yield of 2.7%, appealing to income-focused investors.

Johnson & Johnson
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Johnson & Johnson for these reasons:

  • Despite strong earnings, the stock has a relatively high price-to-earnings (PE) ratio of 20.42, which may suggest that the stock is overvalued compared to its earnings.
  • The company has a debt-to-equity ratio of 0.50, indicating a moderate level of debt, which could pose risks if interest rates rise or if the company faces financial challenges.
  • Recent insider selling, including a significant transaction by an executive vice president, may raise concerns about the company's future prospects and insider confidence.
  • Analysts have mixed ratings, with eight holding a "Hold" rating, suggesting that some investors may be cautious about the stock's short-term performance.
  • Market volatility and external economic factors could impact Johnson & Johnson's performance, making it a riskier investment in uncertain times.

JNJ Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $200.06, with a high forecast of $215.00 and a low forecast of $153.00.

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last twelve months. There are currently 8 hold ratings, 14 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JNJ shares.

According to analysts, Johnson & Johnson's stock has a predicted upside of 3.20% based on their 12-month stock forecasts.

Over the previous 90 days, Johnson & Johnson's stock had 5 upgrades by analysts.

Analysts like Johnson & Johnson more than other "medical" companies. The consensus rating for Johnson & Johnson is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how JNJ compares to other companies.


This page (NYSE:JNJ) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners